Clinical Trial Search

Primary: Count of Participants That Experience 1 Year Relapse Free Survival After Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Using the Thomas Jefferson University…

Primary: Number of Disease-free Patients — 5; 12 participants — p=0.0493

Primary: Count of Participants That Experience Overall Response Following 4 Cycles of the Combination Regimen BBd — 13 Participants

Primary: Percentage of Participants With Complete Response (CR) or Partial Response [PR, Objective Response Rate (ORR)] — 0.0; 4.8; 0.0 percentage of participants

Primary: Change From Baseline in Parent Rated Social Responsiveness Scale (SRS) Scores During Treatment. — 9.73; 3.18 units on a scale — p=0.0275

Primary: Change From Baseline in Appendicular Lean Body Mass (aLBM) at Week 12 — 0.297; 0.741; 1.018; 1.357 percentage change in aLBM (3 limbs) — p=0.527

Primary: Latency to Persistent Sleep — -22.7; -39.1; -37.5 minutes

Primary: PSA Response, as Defined by ≥ 50% Decrease in PSA From Baseline — 1 Participants

Primary: Percentage of Participants Achieving Objective Response Rate (ORR) (Complete Response + Partial Response) — 10; 6; 7 Percentage of Participants

Primary: Proportion of Patients Under Each Treatment Arm Who Experienced a Mean Symptom Increase of 2 Units or More From Baseline to 6 Weeks. — 0; 2; 1; 2 Participants

Primary: Progression-Free Survival (PFS) — 2.0; 3.1 months

Primary: Fibromyalgia Impact Questionnaire — 49.9; 37.5; 39.9; 33.4 units on a scale

Primary: Day 56 Treatment Success — 57; 72; 43; 47 percentage of participants

Primary: Number of Subjects With Serum Bactericidal Assay Using Rabbit Complement Against Neisseria Meningitides Serogroups A, C, W-135, Y (rSBA-MenA, rSBA-MenC, rSBA-MenW-135…

Primary: Event-free Survival (EFS) — 1 Participants